
|Articles|July 11, 2012
Introduction and Overview of Results from CLEOPATRA Trial
AJMC's Co-Editor-in-Chief, Michael E. Chernew, PhD, Lee N. Newcomer, MD, MHA, UnitedHealthcare, and Sandra M. Swain, MD, Washington Cancer Institute, Medstar Washington Hospital Center.
Advertisement
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
4
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
5













































